Press releases appear below, filter by date.
Astellas UK is suspended from membership of the ABPI
The arrangements for advisory board meetings are often the subject of enquiries to the PMCPA for informal advice.
Both companies have brought discredit upon, and reduced confidence in, the pharmaceutical industry.
In 2016 pharmaceutical companies will disclose details of certain transfers of value made to healthcare professionals (HCPs), other relevant decision makers (ORDMs) and healthcare organisations (HCOs) during 2015 on the ABPI central platform.
The PMCPA has issued informal guidance on certification which examines in particular the requirements in relation to projects involving a number of companies and which reflects the changes in the 2016 ABPI Code.
The new Interactive version of the 2016 ABPI Code of Practice for the pharmaceutical industry is available on the PMCPA website from today.
The 2016 Code can be downloaded here
The President of the ABPI and the Director of the PMCPA have recently highlighted the need to ensure that advisory board meetings meet the requirements of the Code.
Proposals to amend the ABPI Code of Practice for the Pharmaceutical Industry and the PMCPA Constitution and Procedure were agreed at the Half Yearly General Meeting of the ABPI on 11 November. Further changes were agreed at a special meeting of the ABPI on 1 December.
We are seeking to appoint a new independent member, from an independent body involved with providing information on medicines, to the Code of Practice Appeal Board in 2016.
Proposals for amendment of the ABPI Code of Practice for the Pharmaceutical Industry and the PMCPA Constitution and Procedure were agreed at the Half Yearly General Meeting of the ABPI on 11 November.
Further consultation on proposed changes to the ABPI Code of Practice for the Pharmaceutical Industry.
